Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00539461
Other study ID # 248.638
Secondary ID
Status Completed
Phase N/A
First received September 28, 2007
Last updated October 31, 2013
Start date February 2007

Study information

Verified date October 2013
Source Boehringer Ingelheim
Contact n/a
Is FDA regulated No
Health authority Germany: BfArM (Bundesinstitut für Arzneimittel und Medizinalprodukte
Study type Observational

Clinical Trial Summary

In this German non-interventional observational study 1980 patients diagnosed with Restless Legs Syndrome (RLS) will be investigated by 990 General Practitioners across all federal states in Germany. Both moderate to severe RLS patients, with or without previous RLS treatment, suffering from RLS symptoms like a desire to move the extremities usually associated with some discomfort, motor restlessness and worsening of symptoms at rest with at least temporary relief by activity, worsening of symptoms later in the day or at night, are eligible for this study, if it is planned to initiate therapy with pramipexole or to add pramipexole to a previously given, insufficient therapy. Three visits are planned to be documented in this PMS study, one baseline visit, visit two after the end of pramipexole titration and visit three after 12 weeks of treatment. Evaluations and visits are to be carried out and documented only if part of routine medical practice. The main goal of observational studies is to determine how pramipexole treatment works when applied in actual practice and thus maximise external validity. In actual practice patients who have been excluded in the clinical registration trials of PPX in moderate to severe primary RLS (i.e. those with certain disease histories, co-morbidities and/or demographic characteristics) will be treated with PPX. Thus in addition during this observational study information on the efficacy and safety of PPX in those patients will be obtained. The objectives of this PMS study are:

- To evaluate the treatment effect of pramipexole on RLS severity and general improvement as measured by IRLS and CGI-I.

- To evaluate quality of life of RLS patients as measured by the Restless Legs Syndrome Quality of Life questionnaire (RLS-QoL).

- To evaluate the safety profile of PPX in a natural study population.


Recruitment information / eligibility

Status Completed
Enrollment 2023
Est. completion date
Est. primary completion date November 2007
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Diagnosis of primary RLS

2. Indication for RLS treatment with SifrolĀ® (pramipexole)

3. Male or female patients aged at least 18 years.

Exclusion Criteria:

1. Any contraindications according to the Summary of Product Characteristics (SPC): hypersensitivity to pramipexole or to any of the excipients.

2. Ongoing treatment with SifrolĀ® (pramipexole).

Study Design

Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
Germany Boehringer Ingelheim Investigational Site Aalen
Germany Boehringer Ingelheim Investigational Site Aarbergen
Germany Boehringer Ingelheim Investigational Site Adendorf
Germany Boehringer Ingelheim Investigational Site Aham
Germany Boehringer Ingelheim Investigational Site Ahaus
Germany Boehringer Ingelheim Investigational Site Ahlen
Germany Boehringer Ingelheim Investigational Site Ahorntal
Germany Boehringer Ingelheim Investigational Site Aichach
Germany Boehringer Ingelheim Investigational Site Aislingen
Germany Boehringer Ingelheim Investigational Site Albstadt
Germany Boehringer Ingelheim Investigational Site Aldenhoven
Germany Boehringer Ingelheim Investigational Site Aldingen
Germany Boehringer Ingelheim Investigational Site Alfeld
Germany Boehringer Ingelheim Investigational Site Alpirsbach
Germany Boehringer Ingelheim Investigational Site Alsdorf
Germany Boehringer Ingelheim Investigational Site Altena
Germany Boehringer Ingelheim Investigational Site Altenstadt
Germany Boehringer Ingelheim Investigational Site Altomünster
Germany Boehringer Ingelheim Investigational Site Alveslohe
Germany Boehringer Ingelheim Investigational Site Amberg
Germany Boehringer Ingelheim Investigational Site Ammerbuch
Germany Boehringer Ingelheim Investigational Site Andernach
Germany Boehringer Ingelheim Investigational Site Anklam
Germany Boehringer Ingelheim Investigational Site Apolda
Germany Boehringer Ingelheim Investigational Site Armsheim
Germany Boehringer Ingelheim Investigational Site Arzberg
Germany Boehringer Ingelheim Investigational Site Aschaffenburg
Germany Boehringer Ingelheim Investigational Site Aschersleben
Germany Boehringer Ingelheim Investigational Site Aschheim
Germany Boehringer Ingelheim Investigational Site Attendorn
Germany Boehringer Ingelheim Investigational Site Auerbach
Germany Boehringer Ingelheim Investigational Site Augsburg
Germany Boehringer Ingelheim Investigational Site Aurich
Germany Boehringer Ingelheim Investigational Site Babensham
Germany Boehringer Ingelheim Investigational Site Backnang
Germany Boehringer Ingelheim Investigational Site Bad Arolsen
Germany Boehringer Ingelheim Investigational Site Bad Berleburg
Germany Boehringer Ingelheim Investigational Site Bad Bevensen
Germany Boehringer Ingelheim Investigational Site Bad Düben
Germany Boehringer Ingelheim Investigational Site Bad Dürrenberg
Germany Boehringer Ingelheim Investigational Site Bad Dürrheim
Germany Boehringer Ingelheim Investigational Site Bad Ems
Germany Boehringer Ingelheim Investigational Site Bad Essen
Germany Boehringer Ingelheim Investigational Site Bad Kreuznach
Germany Boehringer Ingelheim Investigational Site Bad Laasphe
Germany Boehringer Ingelheim Investigational Site Bad Langensalza
Germany Boehringer Ingelheim Investigational Site Bad Lausick
Germany Boehringer Ingelheim Investigational Site Bad Münstereifel
Germany Boehringer Ingelheim Investigational Site Bad Oeynhausen
Germany Boehringer Ingelheim Investigational Site Bad Salzungen
Germany Boehringer Ingelheim Investigational Site Bad Schwalbach
Germany Boehringer Ingelheim Investigational Site Bad Schwartau
Germany Boehringer Ingelheim Investigational Site Bad Segeberg
Germany Boehringer Ingelheim Investigational Site Bad Tennstedt
Germany Boehringer Ingelheim Investigational Site Bad Waldsee
Germany Boehringer Ingelheim Investigational Site Baden-Baden
Germany Boehringer Ingelheim Investigational Site Bahrdorf
Germany Boehringer Ingelheim Investigational Site Baltmannsweiler
Germany Boehringer Ingelheim Investigational Site Bamberg
Germany Boehringer Ingelheim Investigational Site Barleben
Germany Boehringer Ingelheim Investigational Site Bärnau
Germany Boehringer Ingelheim Investigational Site Baunatal
Germany Boehringer Ingelheim Investigational Site Bautzen
Germany Boehringer Ingelheim Investigational Site Bayreuth
Germany Boehringer Ingelheim Investigational Site Beckum
Germany Boehringer Ingelheim Investigational Site Beeskow
Germany Boehringer Ingelheim Investigational Site Bellheim
Germany Boehringer Ingelheim Investigational Site Belm
Germany Boehringer Ingelheim Investigational Site Bensheim
Germany Boehringer Ingelheim Investigational Site Berching
Germany Boehringer Ingelheim Investigational Site Bergfelde
Germany Boehringer Ingelheim Investigational Site Bergheim
Germany Boehringer Ingelheim Investigational Site Bergisch Gladbach
Germany Boehringer Ingelheim Investigational Site Berkheim
Germany Boehringer Ingelheim Investigational Site Berlin
Germany Boehringer Ingelheim Investigational Site Berne
Germany Boehringer Ingelheim Investigational Site Bernsdorf
Germany Boehringer Ingelheim Investigational Site Betzdorf
Germany Boehringer Ingelheim Investigational Site Biebertal
Germany Boehringer Ingelheim Investigational Site Bielefeld
Germany Boehringer Ingelheim Investigational Site Bienenbüttel
Germany Boehringer Ingelheim Investigational Site Bippen
Germany Boehringer Ingelheim Investigational Site Birkenfeld
Germany Boehringer Ingelheim Investigational Site Birkenwerder
Germany Boehringer Ingelheim Investigational Site Blankenhain
Germany Boehringer Ingelheim Investigational Site Blaustein
Germany Boehringer Ingelheim Investigational Site Blieskastel
Germany Boehringer Ingelheim Investigational Site Bobritzsch
Germany Boehringer Ingelheim Investigational Site Bocholt
Germany Boehringer Ingelheim Investigational Site Bochum
Germany Boehringer Ingelheim Investigational Site Bockenem
Germany Boehringer Ingelheim Investigational Site Bodelshausen
Germany Boehringer Ingelheim Investigational Site Bodenfelde
Germany Boehringer Ingelheim Investigational Site Bodenkirchen
Germany Boehringer Ingelheim Investigational Site Bodenwöhr
Germany Boehringer Ingelheim Investigational Site Bodman-Ludwigshafen
Germany Boehringer Ingelheim Investigational Site Böhlen
Germany Boehringer Ingelheim Investigational Site Bollendorf
Germany Boehringer Ingelheim Investigational Site Bonn
Germany Boehringer Ingelheim Investigational Site Bopfingen
Germany Boehringer Ingelheim Investigational Site Borgholzhausen
Germany Boehringer Ingelheim Investigational Site Borken
Germany Boehringer Ingelheim Investigational Site Borna
Germany Boehringer Ingelheim Investigational Site Bornheim
Germany Boehringer Ingelheim Investigational Site Bösel
Germany Boehringer Ingelheim Investigational Site Bottendorf
Germany Boehringer Ingelheim Investigational Site Bottmersdorf
Germany Boehringer Ingelheim Investigational Site Bottrop
Germany Boehringer Ingelheim Investigational Site Bovenden
Germany Boehringer Ingelheim Investigational Site Brake
Germany Boehringer Ingelheim Investigational Site Brandenburg
Germany Boehringer Ingelheim Investigational Site Brannenburg
Germany Boehringer Ingelheim Investigational Site Braunschweig
Germany Boehringer Ingelheim Investigational Site Brechen
Germany Boehringer Ingelheim Investigational Site Breitenbrunn
Germany Boehringer Ingelheim Investigational Site Bremen
Germany Boehringer Ingelheim Investigational Site Bremerhaven
Germany Boehringer Ingelheim Investigational Site Brensbach
Germany Boehringer Ingelheim Investigational Site Breuberg
Germany Boehringer Ingelheim Investigational Site Bruchköbel
Germany Boehringer Ingelheim Investigational Site Brunsbüttel
Germany Boehringer Ingelheim Investigational Site Buchbach
Germany Boehringer Ingelheim Investigational Site Bückeburg
Germany Boehringer Ingelheim Investigational Site Buckow
Germany Boehringer Ingelheim Investigational Site Büdelsdorf
Germany Boehringer Ingelheim Investigational Site Bunde
Germany Boehringer Ingelheim Investigational Site Burg
Germany Boehringer Ingelheim Investigational Site Burgau
Germany Boehringer Ingelheim Investigational Site Burgdorf
Germany Boehringer Ingelheim Investigational Site Burgpreppach
Germany Boehringer Ingelheim Investigational Site Burtenbach
Germany Boehringer Ingelheim Investigational Site Büttelborn
Germany Boehringer Ingelheim Investigational Site Buttstädt
Germany Boehringer Ingelheim Investigational Site Butzbach
Germany Boehringer Ingelheim Investigational Site Cadolzburg
Germany Boehringer Ingelheim Investigational Site Calbe
Germany Boehringer Ingelheim Investigational Site Calberlah
Germany Boehringer Ingelheim Investigational Site Castrop-Rauxel
Germany Boehringer Ingelheim Investigational Site Celle
Germany Boehringer Ingelheim Investigational Site Chemnitz
Germany Boehringer Ingelheim Investigational Site Cochem
Germany Boehringer Ingelheim Investigational Site Coppenbrügge
Germany Boehringer Ingelheim Investigational Site Crimmitschau
Germany Boehringer Ingelheim Investigational Site Crivitz
Germany Boehringer Ingelheim Investigational Site Cuxhaven
Germany Boehringer Ingelheim Investigational Site Dabel
Germany Boehringer Ingelheim Investigational Site Darmstadt
Germany Boehringer Ingelheim Investigational Site Dassow
Germany Boehringer Ingelheim Investigational Site Datteln
Germany Boehringer Ingelheim Investigational Site Daun
Germany Boehringer Ingelheim Investigational Site Deggendorf
Germany Boehringer Ingelheim Investigational Site Deidesheim
Germany Boehringer Ingelheim Investigational Site Deining
Germany Boehringer Ingelheim Investigational Site Delitzsch
Germany Boehringer Ingelheim Investigational Site Demen
Germany Boehringer Ingelheim Investigational Site Denkendorf
Germany Boehringer Ingelheim Investigational Site Dessau
Germany Boehringer Ingelheim Investigational Site Detmold
Germany Boehringer Ingelheim Investigational Site Dettenheim
Germany Boehringer Ingelheim Investigational Site Deuben
Germany Boehringer Ingelheim Investigational Site Deutzen
Germany Boehringer Ingelheim Investigational Site Diepholz
Germany Boehringer Ingelheim Investigational Site Dillingen
Germany Boehringer Ingelheim Investigational Site Dingolfing
Germany Boehringer Ingelheim Investigational Site Dinkelsbühl
Germany Boehringer Ingelheim Investigational Site Dinslaken
Germany Boehringer Ingelheim Investigational Site Dissen
Germany Boehringer Ingelheim Investigational Site Dogern
Germany Boehringer Ingelheim Investigational Site Dollern
Germany Boehringer Ingelheim Investigational Site Donaueschingen
Germany Boehringer Ingelheim Investigational Site Dörentrup
Germany Boehringer Ingelheim Investigational Site Dormagen
Germany Boehringer Ingelheim Investigational Site Dornstetten
Germany Boehringer Ingelheim Investigational Site Dörpen
Germany Boehringer Ingelheim Investigational Site Dorsten
Germany Boehringer Ingelheim Investigational Site Dortmund
Germany Boehringer Ingelheim Investigational Site Dreieich
Germany Boehringer Ingelheim Investigational Site Drensteinfurt
Germany Boehringer Ingelheim Investigational Site Dresden
Germany Boehringer Ingelheim Investigational Site Driedorf
Germany Boehringer Ingelheim Investigational Site Duderstadt
Germany Boehringer Ingelheim Investigational Site Duisburg
Germany Boehringer Ingelheim Investigational Site Dummerstorf
Germany Boehringer Ingelheim Investigational Site Düren
Germany Boehringer Ingelheim Investigational Site Düsseldorf
Germany Boehringer Ingelheim Investigational Site Ebergötzen
Germany Boehringer Ingelheim Investigational Site Ebermannstadt
Germany Boehringer Ingelheim Investigational Site Eberstadt
Germany Boehringer Ingelheim Investigational Site Ebhausen
Germany Boehringer Ingelheim Investigational Site Edewecht
Germany Boehringer Ingelheim Investigational Site Edling
Germany Boehringer Ingelheim Investigational Site Egelsbach
Germany Boehringer Ingelheim Investigational Site Ehingen
Germany Boehringer Ingelheim Investigational Site Eilenburg
Germany Boehringer Ingelheim Investigational Site Eisenhüttenstadt
Germany Boehringer Ingelheim Investigational Site Eiterfeld
Germany Boehringer Ingelheim Investigational Site Eitorf
Germany Boehringer Ingelheim Investigational Site Ellwangen
Germany Boehringer Ingelheim Investigational Site Elmshorn
Germany Boehringer Ingelheim Investigational Site Emersacker
Germany Boehringer Ingelheim Investigational Site Emmendingen
Germany Boehringer Ingelheim Investigational Site Emsdetten
Germany Boehringer Ingelheim Investigational Site Enger
Germany Boehringer Ingelheim Investigational Site Enkenbach-Alsenborn
Germany Boehringer Ingelheim Investigational Site Ennepetal
Germany Boehringer Ingelheim Investigational Site Ennigerloh
Germany Boehringer Ingelheim Investigational Site Eppstein
Germany Boehringer Ingelheim Investigational Site Erding
Germany Boehringer Ingelheim Investigational Site Erftstadt
Germany Boehringer Ingelheim Investigational Site Erkrath
Germany Boehringer Ingelheim Investigational Site Erligheim
Germany Boehringer Ingelheim Investigational Site Erndtebrück
Germany Boehringer Ingelheim Investigational Site Erolzheim
Germany Boehringer Ingelheim Investigational Site Eschborn
Germany Boehringer Ingelheim Investigational Site Eschelbronn
Germany Boehringer Ingelheim Investigational Site Eschweiler
Germany Boehringer Ingelheim Investigational Site Eslohe
Germany Boehringer Ingelheim Investigational Site Espenhain
Germany Boehringer Ingelheim Investigational Site Essen
Germany Boehringer Ingelheim Investigational Site Esslingen
Germany Boehringer Ingelheim Investigational Site Euskirchen
Germany Boehringer Ingelheim Investigational Site Filderstadt
Germany Boehringer Ingelheim Investigational Site Floh-Seligenthal
Germany Boehringer Ingelheim Investigational Site Flöha
Germany Boehringer Ingelheim Investigational Site Forbach
Germany Boehringer Ingelheim Investigational Site Forchheim
Germany Boehringer Ingelheim Investigational Site Frankenberg
Germany Boehringer Ingelheim Investigational Site Frankenthal
Germany Boehringer Ingelheim Investigational Site Frankfurt
Germany Boehringer Ingelheim Investigational Site Freiberg
Germany Boehringer Ingelheim Investigational Site Freiburg
Germany Boehringer Ingelheim Investigational Site Freigericht
Germany Boehringer Ingelheim Investigational Site Freudenstadt
Germany Boehringer Ingelheim Investigational Site Freyung
Germany Boehringer Ingelheim Investigational Site Friedland
Germany Boehringer Ingelheim Investigational Site Friedrichshafen
Germany Boehringer Ingelheim Investigational Site Friedrichsthal
Germany Boehringer Ingelheim Investigational Site Frohburg
Germany Boehringer Ingelheim Investigational Site Fulda
Germany Boehringer Ingelheim Investigational Site Fürstenwalde
Germany Boehringer Ingelheim Investigational Site Furtwangen
Germany Boehringer Ingelheim Investigational Site Füssen
Germany Boehringer Ingelheim Investigational Site Gangelt
Germany Boehringer Ingelheim Investigational Site Gardelegen
Germany Boehringer Ingelheim Investigational Site Garmisch-Partenkirchen
Germany Boehringer Ingelheim Investigational Site Gars
Germany Boehringer Ingelheim Investigational Site Gaußig
Germany Boehringer Ingelheim Investigational Site Gebesee
Germany Boehringer Ingelheim Investigational Site Geesthacht
Germany Boehringer Ingelheim Investigational Site Gelbensande
Germany Boehringer Ingelheim Investigational Site Gelsenkirchen
Germany Boehringer Ingelheim Investigational Site Gensingen
Germany Boehringer Ingelheim Investigational Site Georgsmarienhütte
Germany Boehringer Ingelheim Investigational Site Gera
Germany Boehringer Ingelheim Investigational Site Gerbstedt
Germany Boehringer Ingelheim Investigational Site Germaringen
Germany Boehringer Ingelheim Investigational Site Germering
Germany Boehringer Ingelheim Investigational Site Germersheim
Germany Boehringer Ingelheim Investigational Site Gevelsberg
Germany Boehringer Ingelheim Investigational Site Gießen
Germany Boehringer Ingelheim Investigational Site Gifhorn
Germany Boehringer Ingelheim Investigational Site Gilserberg
Germany Boehringer Ingelheim Investigational Site Gladbeck
Germany Boehringer Ingelheim Investigational Site Gleichen
Germany Boehringer Ingelheim Investigational Site Goch
Germany Boehringer Ingelheim Investigational Site Gochsheim
Germany Boehringer Ingelheim Investigational Site Göllheim
Germany Boehringer Ingelheim Investigational Site Göllingen
Germany Boehringer Ingelheim Investigational Site Gomaringen
Germany Boehringer Ingelheim Investigational Site Göttingen
Germany Boehringer Ingelheim Investigational Site Grafenau
Germany Boehringer Ingelheim Investigational Site Gransee
Germany Boehringer Ingelheim Investigational Site Grassau
Germany Boehringer Ingelheim Investigational Site Greiz
Germany Boehringer Ingelheim Investigational Site Greven
Germany Boehringer Ingelheim Investigational Site Grevesmühlen
Germany Boehringer Ingelheim Investigational Site Griesheim
Germany Boehringer Ingelheim Investigational Site Grömitz
Germany Boehringer Ingelheim Investigational Site Gronau
Germany Boehringer Ingelheim Investigational Site Groß Grönau
Germany Boehringer Ingelheim Investigational Site Groß Quenstedt
Germany Boehringer Ingelheim Investigational Site Groß-Zimmern
Germany Boehringer Ingelheim Investigational Site Großalmerode
Germany Boehringer Ingelheim Investigational Site Großbottwar
Germany Boehringer Ingelheim Investigational Site Großefehn
Germany Boehringer Ingelheim Investigational Site Großhabersdorf
Germany Boehringer Ingelheim Investigational Site Großkorbetha
Germany Boehringer Ingelheim Investigational Site Großlangheim
Germany Boehringer Ingelheim Investigational Site Grünbach
Germany Boehringer Ingelheim Investigational Site Gummersbach
Germany Boehringer Ingelheim Investigational Site Güstrow
Germany Boehringer Ingelheim Investigational Site Haag
Germany Boehringer Ingelheim Investigational Site Hagen
Germany Boehringer Ingelheim Investigational Site Haigerloch
Germany Boehringer Ingelheim Investigational Site Haldensleben
Germany Boehringer Ingelheim Investigational Site Halle
Germany Boehringer Ingelheim Investigational Site Hamburg
Germany Boehringer Ingelheim Investigational Site Hamm
Germany Boehringer Ingelheim Investigational Site Hamminkeln
Germany Boehringer Ingelheim Investigational Site Hanau
Germany Boehringer Ingelheim Investigational Site Hanerau-Hademarschen
Germany Boehringer Ingelheim Investigational Site Hannover
Germany Boehringer Ingelheim Investigational Site Harpstedt
Germany Boehringer Ingelheim Investigational Site Harsefeld
Germany Boehringer Ingelheim Investigational Site Harsewinkel
Germany Boehringer Ingelheim Investigational Site Haselünne
Germany Boehringer Ingelheim Investigational Site Hattersheim
Germany Boehringer Ingelheim Investigational Site Hattingen
Germany Boehringer Ingelheim Investigational Site Havixbeck
Germany Boehringer Ingelheim Investigational Site Hedersleben
Germany Boehringer Ingelheim Investigational Site Heek
Germany Boehringer Ingelheim Investigational Site Heide
Germany Boehringer Ingelheim Investigational Site Heidelberg
Germany Boehringer Ingelheim Investigational Site Heilbronn
Germany Boehringer Ingelheim Investigational Site Heimsheim
Germany Boehringer Ingelheim Investigational Site Heinsberg
Germany Boehringer Ingelheim Investigational Site Hellenthal

Sponsors (1)

Lead Sponsor Collaborator
Boehringer Ingelheim

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline in IRLS total score after 12 weeks 12 weeks No
Primary CGI-I responder rate after 12 weeks 12 weeks No
Primary Time to reach maintenance dose 12 weeks No
Primary Change from baseline in RLS-QoL total score after 12 weeks 12 weeks No
Secondary Change from baseline in IRLS score after 1-4 weeks 4 weeks No
Secondary Change in IRLS items after 12 weeks 12 weeks No
Secondary Final dose distribution 12 weeks No
Secondary Incidence, relationship and seriousness of adverse events 12 weeks No
Secondary Number of premature discontinuations 12 weeks No
See also
  Status Clinical Trial Phase
Recruiting NCT04786314 - The Effect of Hot and Cold Water Application on Pregnant Women With Restless Leg Syndrome N/A
Completed NCT01455012 - Effects of Neupro on Cardiovascular Observations in Patients With Restless Legs Syndrome Phase 4
Terminated NCT01192503 - Safety and Efficacy of Rasagiline in Restless Legs Syndrome Phase 2/Phase 3
Completed NCT00530530 - ASP8825 - Study in Patients With Restless Legs Syndrome Phase 2
Completed NCT00721279 - Sifrol (Pramipexole) Onset of Action and Impact: a 12-weeks Observational Study in Patients With Primary Restless Legs Syndrome N/A
Completed NCT00375284 - A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS Phase 4
Completed NCT00942253 - Exercise Training in Dialysis Patients With Restless Legs Syndrome (RLS) Phase 2
Completed NCT00479531 - Sequential Compression Devices for Treatment of Restless Legs Syndrome Phase 3
Recruiting NCT05581576 - Pitolisant in Refractory Restless Legs Syndrome Phase 4
Active, not recruiting NCT03218969 - Treatment of Restless Leg Syndrome (RLS) Augmentation With Ecopipam, a D1 Specific Antagonist Phase 1/Phase 2
Recruiting NCT04144790 - Impact of Iron Supplementation Treatment on Brain Iron Concentrations
Completed NCT05787080 - Massage, Oxidative and Antioxidant Enzymes in Hemodialysis Patients With Restless Legs Syndrome(RLS) N/A
Not yet recruiting NCT05529095 - Sublingual Apomorphine in Refractory Restless Legs Syndrome Phase 4
Recruiting NCT05044520 - Clinical Features Associated With Restless Legs Syndrome.
Withdrawn NCT03849001 - Impact of Acute Leg Cycling at Various Intensities on RLS Severity in Persons With MS N/A
Completed NCT03076541 - Cardiovascular Variability, Heart Rate Response, and Electromyogram Power Associated With Periodic Leg Movements. N/A
Recruiting NCT04145674 - A Proof of Concept, Phase 2, Double-blind, Randomized Trial With d-Methadone Product Versus Placebo Phase 2
Completed NCT02532608 - Infra-slow Oscillations During Sleep N/A
Completed NCT01528462 - Sleep Disorders Managed and Assessed Rapidly in Transient Ischemic Attack (TIA) and In Early Stroke
Completed NCT00748098 - Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance Phase 3

External Links